# A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

> **NCT01455701** · PHASE1 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 11 (actual)

## Conditions studied

- Juvenile Idiopathic Arthritis

## Interventions

- **DRUG:** Tocilizumab

## Key facts

- **NCT ID:** NCT01455701
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10-26
- **Primary completion:** 2016-07-28
- **Final completion:** 2017-07-13
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2019-11-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01455701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01455701, "A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01455701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*